Skip to main content
KYONGBO PHARMACEUTICAL CO., LTD. logo

KYONGBO PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 214390 ISIN · KR7214390007 LEI · 988400YKOM1CHDS6R917 KO Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 214390

About KYONGBO PHARMACEUTICAL CO., LTD.

https://www.kbpharma.co.kr/en/home

Kyongbo Pharmaceutical Co., Ltd. is a pharmaceutical company specializing in the research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished drug products. The company also operates as a Contract Development and Manufacturing Organization (CDMO), offering integrated services from early-stage development through to commercial cGMP production. Its core product portfolio includes a diverse range of APIs, such as sterile and non-sterile cephalosporins, carbapenem antibiotics, and high-potency cytotoxic anti-cancer agents. In addition to APIs, the company manufactures finished dosage forms, including solid oral medications and sterile injectables. Kyongbo Pharmaceutical utilizes dedicated and segregated manufacturing facilities to produce its specialized product lines, supported by a strong commitment to research and innovation in API synthesis.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 93% confidence The document is titled “분기보고서” (Quarterly Report) for the 1st quarter of fiscal 2026 (2026.01.01–2026.03.31). It contains in-depth financial tables (segment revenues, cost of goods, production capacity, etc.), management’s discussion of business operations, major events, changes in capital, share counts, and detailed product‐line performance. It is a full interim/quarterly report with actual financial data, not an announcement or simple notice. According to the classification definitions, this corresponds to an Interim / Quarterly Report. Q1 2026
2026-05-15 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 90% confidence The document is a public compliance announcement (“공정공시”) of preliminary (unaudited) quarterly operating results (revenue, operating profit, pre-tax profit, net income) for Q1 2026 compared to prior periods. It provides high-level financial metrics and notes these figures are provisional and will be finalized after audit. This matches an initial announcement of quarterly financial results (Earnings Release), not a full interim report or annual filing. Q1 2026
2026-04-29 Korean
단일판매ㆍ공급계약해지
Regulatory Filings Classification · 50% confidence The document is a corporate disclosure in Korean detailing the termination of a single sales and supply contract (단일판매ㆍ공급계약 해지). It lists contract termination specifics such as amounts, term dates, counterparty, and reasons. This is not a financial report (Annual Report, Interim Report), not earnings, not a board change, not a share transaction, and not a prescribed corporate governance or ESG report. It is a general regulatory announcement of a contract termination. Under the given taxonomy, it falls under the fallback category ‘Regulatory Filings’ (RNS).
2026-04-10 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a post-meeting announcement detailing the results of the 2026 regular shareholders’ meeting: approval of financial statements, dividend resolutions, director appointments, record date, vote counts and percentages, and related agenda items. This aligns with a Declaration of Voting Results & Voting Rights Announcements rather than a shareholder presentation or full annual report.
2026-03-26 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 85% confidence The document is a statutory notice submitted to the Korean Financial Services Commission and Korea Exchange announcing the appointment (and potentially dismissal/resignation) of an outside director. It lists company name, representative, date, details of the outside director change, and biographical data of the newly appointed director. This clearly constitutes an Announcement of changes in the company’s board of directors or senior management, matching the definition for Board/Management Information (MANG).
2026-03-26 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 80% confidence The document is a voluntary regulatory disclosure (‘자율공시’) by a Korean company detailing its ‘corporate value enhancement plan’ in connection with high‐dividend status under tax law. It is neither a financial results release, dividend notice, ESG report, management change, nor any US-style filing (10-K, DEF 14A, etc.). It does not announce an upcoming report nor provide proxy materials. This is a standalone regulatory filing that does not fit any of the more specific categories and thus falls under the general “Regulatory Filings” (RNS) fallback category.
2026-03-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.